Cetirizine Versus Diphenhydramine in MS Patients during Anti-CD20 Infusion Therapy
A study is currently planned to compare the tolerability and safety of cetirizine versus diphenhydramine in Multiple Sclerosis (MS) patients undergoing anti-CD20 infusion therapy. The tolerability will be measured using the Stanford Sleepiness Scale over approximately one year of follow-up.
- Tags
- #MSResearch
- Most relevant to
- —
- Source
- Read original source
Why it matters
Understanding which pre-medication is better tolerated can improve patient comfort and safety during infusion therapy for MS, but the study has not yet reported any results.
What this does not prove
Since no results are available, we do not know the outcomes or efficacy of either medication. Planned enrollment and endpoints are not findings.
Next milestone
No next milestone was established from the available source.
Study facts
- Study design
- Not reported
- Participants / samples
- Not reported
- Randomised
- Yes
- Controlled
- Yes
- Primary endpoint met
- Not reported
- Relevant MS type
- Not reported
- Publication date
- Not reported
- Evidence reviewed
- Trial registry record
- Regulatory approval
- Not reported
- Research areas
- Not classified
Original sources
Supporting passages (8)
study phase"description": "Total duration, in minutes, that the participant occupies the infusion chair during each study visit.
randomized"description": "Total duration, in minutes, that the participant occupies the infusion chair during each study visit.
controlled"description": "Total duration, in minutes, that the participant occupies the infusion chair during each study visit.
interventionThe study will also compare the safety of cetirizine versus diphenhydramine as a pre-medication for preventing infusion reactions in MS patients receiving anti-CD20 infusion therapy."
primary endpoint"measure": "Tolerability as Measured by Sleepiness (Stanford Sleepiness Scale)",
follow up"timeFrame": "Through study completion, approximately 1 year (assessed at each infusion visit)"
findingsThe study will also compare the safety of cetirizine versus diphenhydramine as a pre-medication for preventing infusion reactions in MS patients receiving anti-CD20 infusion therapy."
limitationsNo results are posted. Planned enrolment and endpoints are not findings.
AI assessment, not yet reviewed by a person · version 1 · Community votes are separate from evidence review.